Ansun BioPharma, Inc., a San Diego based biotechnology company focused on the development of novel broad spectrum anti-viral biologic therapeutics to combat severe viral respiratory tract infections, has announced the completion of an $85 million Series A financing round.

The round was led by Sinopharm Healthcare Fund and Lilly Asia Ventures.  Additional new investors participating in this round included Lyfe Capital, Yuanming Capital, Matrix Partners China, 3e Bioventures Capital, Oceanpine Capital, VI Ventures, and Joincap Investment.

Ansun plans to use the proceeds from the Series A to fund a Phase 3 clinical trial of its experimental anti-viral medication, DAS181.  The FDA has granted both Fast Track status and Breakthrough therapy designation to DAS181, and Ansun is currently in the planning stage of a Phase 3 trial to treat hospitalized, immunocompromised subjects infected with parainfluenza virus.